nach oben

PharmacoEconomics

Erschienen in:

01.03.2005 | Review Article

International variation in resource utilisation and treatment costs for rheumatoid arthritis

A systematic literature review

verfasst von: Dr Hubertus Rosery, Rito Bergemann, Stefanie Maxion-Bergemann

Erschienen in: PharmacoEconomics | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Recent years have witnessed substantial progress in understanding the cost implications of rheumatoid arthritis (RA). To assess the divergent methodologies and their impact on the resulting cost analyses in RA, we conducted a systematic literature review to summarise the scientific evidence of RA-induced costs.

Sixty-five reviews, models or cost analyses on the burden of illness and general costs associated with RA were identified. They covered the US, Canada, Sweden, the UK, The Netherlands, Germany and Finland. Twenty-four cost analyses provided appropriate data about direct and/or indirect costs. Each study was summarised separately. Costs were discounted to 2003 and converted to US dollars.

The costs per RA-year ranged from $US1503 to $US16 514. However, each study has to be interpreted individually, with consideration given to the study population, indication, age of the study, database used, type of therapy, setting, level of cost differentiation and data derivation. Health technology assessment reports offer sufficient space to adequately describe the composite parts and restrictive elements of different methodological approaches and analyses.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002; 46 (2): 328–46CrossRef

Hunsche E, Chancellor JV, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment: a European literature review. Pharmacoeconomics 2001; 19 Suppl. 1: 1–15PubMedCrossRef

Kvien TK, Glennas A, Knudsrød OG, et al. The prevalence and severity of rheumatoid arthritis in Oslo: results from a country register and a population survey. Scand J Rheumatol 1997; 26 (6: 412–8PubMedCrossRef

Blomqvist P, Feltelius N, Ekbom A, et al. Rheumatoid arthritis in Sweden: drug prescriptions, costs, and adverse drug reactions. J Rheumatol 2000; 27 (5): 1171–7PubMed

van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998; 37 (8): 837–47PubMedCrossRef

Knorr U. A panorama of rheumatic diseases [in German]. Versicherungsmedizin 1994; 46 (6): 212–5PubMed

Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001; 19 (7): 715–28PubMedCrossRef

Gabriel SE. Epidemiology of rheumatic diseases. In: Harris Jr ED, editor. Kellys textbook of rheumatology. Philadelphia (PA): WB Saunders, 2000: 321–33

Lawrence VA, Tugwell P, Gafni A, et al. Acute low back pain and economics of therapy: the iterative loop approach. J Clin Epidemiol 1992; 45 (3): 301–11PubMedCrossRef

10.

Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 2001; 19 (8): 811–8PubMedCrossRef

11.

McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35 (8): 781–90PubMedCrossRef

12.

Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001; 19 (7): 715–28PubMedCrossRef

13.

Merkesdal S, Ruof J, Huelsemann JL, et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001; 28 (3): 657–61PubMed

14.

Pugner KM, Scott DI, Holmes JW, et al. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000; 29 (5): 305–20PubMedCrossRef

15.

Rothfuss J, Mau W, Zeidler H, et al. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997; 26 (5): 771–9PubMedCrossRef

16.

Ruchlin HS, Elkin EB, Paget SA. Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis. Arthritis Care Res 1997; 10 (6: 413–21PubMedCrossRef

17.

Ruof J, Hulsemann JL, Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol 1999; 11 (2): 104–9PubMedCrossRef

18.

Ruof J, Merkesdal S, Huelsemann JL, et al. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics. J Rheumatol 2001; 28 (3): 662–5PubMed

19.

Raftery J. Costing in economic evaluation. BMJ 2003; 320: 1579

20.

Khan SK, Kleijnen J et al. editors. Undertaking systematic reviews of research on effectiveness - CRD’s for those carrying out or commissioning reviews. CRD report no. 42nd ed. York Publishing, March 2001

21.

Al MJ, Michel BC, Rutten FF. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996; 10 (2): 141–51PubMedCrossRef

22.

Jacobs J, Keyserling JA, Britton M, et al. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988; 41 (3): 215–23PubMedCrossRef

23.

Liang MH, Larson M, Thompson M, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27 (5): 522–9PubMedCrossRef

24.

Lubeck DP, Spitz PW, Fries IF, et al. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29 (4): 488–93PubMedCrossRef

25.

Meenan RE Yelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21 (7): 827–33PubMedCrossRef

26.

Stone CE. The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984; 11 (6: 819–27PubMed

27.

Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22PubMedCrossRef

28.

Allaire SH, Meenan RF, Anderson JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis Rheum 1991; 34 (6: 669–78PubMedCrossRef

29.

Anis AH, Tugwell PX, Wells GA, et al. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996; 23 (4): 609–16PubMed

30.

Bedi S, Crook PR, Dick WC, et al. Costs of providing a rheumatological service. Br J Rheumatol 1987; 26 (6): 454–7PubMedCrossRef

31.

Bergquist SR, Felson DT, Prashker MJ, et al. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995; 38 (3): 326–33PubMedCrossRef

32.

Berkanovic E, Hurwicz ML, Batchlor E. Rheumatoid arthritis and the use of medical services. Arthritis Care Res 1991; 4 (1): 12–21PubMedCrossRef

33.

Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000; 42 (6): 588–96PubMedCrossRef

34.

Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84 (2A): 20–4PubMedCrossRef

35.

Brooks RG, Brown MG, Marsh JM, et al. Costs of managing patients at a Canadian rheumatic disease unit. J Rheumatol 1981; 8 (6): 937–48PubMed

36.

Burkhauser RV, Butler IS, Mitchell JM, et al. Effects of arthritis on wage earnings. J Gerontol 1986; 41 (2): 277–81PubMedCrossRef

37.

Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol 1998; 25 Suppl. 53: 8–12

38.

Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996; 275 (11): 858–65PubMedCrossRef

39.

Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43 (10): 2316–27PubMedCrossRef

40.

Chevat C, Pena BM, Al MJ, et al. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 2001; 19 Suppl. 1: 17–32PubMedCrossRef

41.

Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24 (6: 1051–60PubMed

42.

Clarke AE, Levinton C, Joseph L, et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1068–75PubMed

43.

Doeglas D, Summeijer T, Krol B, et al. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995; 54 (6): 455–60PubMedCrossRef

44.

Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38 (8): 1115–9PubMedCrossRef

45.

Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989; 16 (7): 867–84PubMed

46.

Borg G, Allander E, Goobar JE. Links disease-modifying antirheumatic drug therapy: an expensive therapy despite inexpensive drugs. Scand J Rheumatol 1990; 19 (2): 115–21PubMedCrossRef

47.

Kavanaugh A, Heudebert G, Cush J, et al. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25 (5): 297307CrossRef

48.

Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38 (3): 318–25PubMedCrossRef

49.

Thompson MS, Read JL, Hutchings HC, et al. The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988; 15 (1): 35–42PubMed

50.

Verhoeven AC, Bibo JC, Boers M, et al. on behalf of Combinatietherapie Bij Reumatoide Artritis (COBRA) Trial Group. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 1998; 37 (10): 1102–9PubMedCrossRef

51.

Gabriel SE, Campion ME, O’Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37 (3): 333–41PubMedCrossRef

52.

Gabriel SE, Crowson CS, Campion ME, et al. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24 (4): 719–25PubMed

53.

Gabriel SE, Crowson CS, Campion ME, et al. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24 (1): 43–8PubMed

54.

Gabriel SE, Crowson CS, Luthra HS, et al. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26 (6): 1269–74PubMed

55.

Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 Suppl. 2: 51–6CrossRef

56.

Jonsson B, Larsson SE. Functional improvement and costs of hip and knee arthroplasty in destructive rheumatoid arthritis. Scand J Rheumatol 1991; 20 (5): 351–7PubMedCrossRef

57.

Jonsson B, Rehnberg C, Borgquist L, et al. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13,000. Acta Orthop Scand 1992; 63 (2): 207–12PubMedCrossRef

58.

Jonsson D, Husberg M. Socioeconomic costs of rheumatic diseases: implications for technology assessment. Int J Technol Assess Health Care 2000; 16 (4): 1193–200PubMedCrossRef

59.

Kobelt G, Jonsson L, Lindgren P, et al. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46 (9): 2310–9PubMedCrossRef

60.

Kobelt G. Modeling the costs and effects of leflunomide in rheumatoid arthritis. Fur J Health Econom 2002; 3: 180–7CrossRef

61.

Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42 (2): 347–56PubMedCrossRef

62.

Lambert CM, Hurst NP, Forbes IF, et al. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation. BMJ 1998; 316 (7136: 965–9PubMedCrossRef

63.

Lanes SD, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum 1997; 40 (8): 1475–81PubMedCrossRef

64.

Meenan RF, Yelin EH, Henke CJ, et al. The impact of chronic disease. Arthritis Rheum 1981; 24: 544–9PubMedCrossRef

65.

Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis: Western consortium of practising rheumatologists. J Rheumatol 2000; 27 (5): 1156–63PubMed

66.

Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000; 3 (4): 234–52CrossRef

67.

Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis: effect of health care system, severity, and regional difference. J Rheumatol 1986; 13 (2): 277–84PubMed

68.

Yelin E. The costs of rheumatoid arthritis: absolute, incremental and marginal estimates. J Rheumatol 1996; 23 Suppl. 44: 4751

69.

Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42 (6): 1209–18PubMedCrossRef

70.

Maetzel A, Strand V, Tugwell P, et al. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics 2002; 20 (1): 61–70PubMedCrossRef

71.

Marra CA, Esdaile JM, Sun H, et al. The cost of COX inhibitors: how selective should we be? J Rheumatol 2000; 27 (12): 27313

72.

Mau W, Bommann M, Weber H, et al. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM. Br J Rheumatol 1996; 35 (7): 652–9PubMedCrossRef

73.

McCabe CJ, Akehurst RL, Kirsch J, et al. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK. Pharmacoeconomics 1998; 14 (2): 191–9PubMedCrossRef

74.

Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44 (3): 528–34PubMedCrossRef

75.

Nuijten MJ, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19 (10): 1051–64PubMedCrossRef

76.

Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl 1989; 79: 67–96PubMedCrossRef

77.

Magnuson S. Treatment of rheumatoid arthritis: does it affect society’s cost for the disease? J Rheumatol 1996; 23 Suppl. 44: 47–51

78.

Naujoks C. Die volkswirtschaftlichen kosten von rheumy in der bundersrepublik Deutschland [bulletin]. Deutsche Rheuma I Iga, Merkblatt Nr. 6, 7, 1990

79.

Tevar LIRE. Datos socioeconómicos de las emfermadades reumatológicas. 1st National Congress of Liga Reumatológica Espanol; 1997 March 3-7

80.

Rissanen P, Aro S, Sintonen H, et al. Costs and cost-effectiveness in hip and knee replacement. Int J Technol Assess Health Care 1997; 13 (4): 575–88PubMedCrossRef

81.

Ariza-Ariza R, Mestanza-Peralta M, Cardiel MIL Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center. Clin Exp Rheumatol 1997; 15 (1): 75–8PubMed

82.

Cronan TA, Durkin KA, Groessl E, et al. Health care costs for volunteers and non-volunteers in an intervention for people with osteoarthritis. Arthritis Care Res 1997; 10 (1): 36–42PubMedCrossRef

83.

Kochevar RJ, Kaplan RM, Weisman M. Financial and career losses due to rheumatoid arthritis: a pilot study. J Rheumatol 1997; 24 (8): 1527–30PubMed

84.

Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antinflammatory drugs. Arthritis Rheum 1998; 41 (1): 16–25PubMedCrossRef

85.

Badley EM. The economic burden of musculoskeletal disorders in Canada is similar to that for cancer, and may be higher. J Rheumatol 1995; 22 (2): 204–6.PubMed

86.

Magnuson S. Treatment of rheumatoid arthritis: does it affect society’s cost for disease? Br J Rheumatol 1996; 36: 791–5CrossRef

87.

van Tulder MW, Koes BW, Bouter LM. A cost-of-illness study of back pain in The Netherlands. Pain 1995; 62 (2): 233–40PubMedCrossRef

88.

Sangha O, Stucki G. Economic impact of rheumatologic disorders. Curr Opin Rheumatol 1997; 9 (2): 102–5PubMedCrossRef

89.

Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford) 2000; 39 Suppl. 2: 43–50CrossRef

90.

Ward MM. The direct cost of rheumatoid arthritis. Value in Health 2000; 3 (4): 243–52PubMedCrossRef

91.

Yelin EH, Henke CJ, Kramer IS, et al. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985; 312 (15): 962–7PubMedCrossRef

92.

Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30 (5): 50712CrossRef

93.

Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19 Suppl. 1: 49–58PubMedCrossRef

94.

Canadian Coordinating Office for Health Technology Assessment (CCOHTA). A guidance document for the costing process. Version 1.0. Ottawa (ON): Jean-Francois Baladi, 1996: 1–15

95.

Oostenbrink JB, Koopmanschap MA, Rutten FH. Standardization of costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002; 20 (7): 443–54PubMedCrossRef

96.

Pincus T, Mitchell JM, Burkhauser RV. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparisons with rheumatoid arthritis. J Clin Epidemiol 1989; 42 (5): 449–57PubMedCrossRef

97.

Lambert CM, Hurst NP, Lochhead A, et al. A pilot study of the economic cost and clinical outcome of day patient vs inpatient management of active rheumatoid arthritis. Br J Rheumatol 1994; 33 (4): 383–8PubMedCrossRef

98.

Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182–9PubMedCrossRef

99.

Genduso L, Kotsanos J. Review of health economic guidelines in the form of regulations, principles, policies and positions. Drug Inf J 1996; 30: 1003–6CrossRef

100.

Schulenburg J-M, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC 2000; 1: 2–8CrossRef

101.

Gabriel S, Tugwell P, O’Brien B, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003; 30 (4): 891–6PubMed

102.

Gabriel S, Tugwell P, O’Brien B, et al. Report of the OMERACT Task Force on economic evaluation. J Rheumatol 1999; 26 (1): 203–5PubMed

103.

Gabriel S, Tugwell P, Drummond M. Progress towards an OMERACT_ILAR guideline for economic evaluations in rheumatology [letter]. Ann Rheum Dis 2002; 61 (370): 370–3PubMedCrossRef

104.

Greiner W, Schóffski O, Schulenburg JM. The transferability of international economic health-economic results to national study questions. HEPAC 2000; 2: 94–102CrossRef

105.

NICE Appraisal Team. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COC-II inhibitors) for rheumatoid arthritis and osteoarthritis. London: The National Institute of Clinical Excellence, 2000: 1-109

106.

Jobanputra P, Barton P, Bryan S, et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. Report commissoned by NHS R&D HTR Programme. West Midlands DES, University of Birmingham. London: The National Institute for Clinical Excellence, 2001: 1–138

Titel: International variation in resource utilisation and treatment costs for rheumatoid arthritis
A systematic literature review
verfasst von: Dr Hubertus Rosery
Rito Bergemann
Stefanie Maxion-Bergemann
Publikationsdatum: 01.03.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 3/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523030-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

The economic impact of neuropsychiatric symptoms in Alzheimer’s disease

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US

Oral serotonin receptor agonists

A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain

EMEA: for patients or for industry?

The relationship between productivity and health-related QOL